Upload
Featured Recent Articles Topics Login Upload

Search Results for 'trial therapy'

trial therapy published presentations and documents on DocSlides.

Adjuvant therapy in stage III colorectal cancer;
Adjuvant therapy in stage III colorectal cancer;
by fauna
Is less, better?. Ioannis. P. . Boukovinas. MD, ...
Cancer Staging & Grading
Cancer Staging & Grading
by alyssa
Staff Training Meetings. Grace Ordung, Stephanie S...
When is a meta-analysis helpful?
When is a meta-analysis helpful?
by sherrill-nordquist
EBM: 9/18/2012. Evidence-based medicine. 25 year ...
Laquinimod
Laquinimod
by luanne-stotts
, a Once-Daily Oral Drug in Development for The T...
Patient-Centered Management
Patient-Centered Management
by giovanna-bartolotta
in Metastatic Castration-Resistant Prostate Cance...
Physical Therapy
Physical Therapy
by lois-ondreau
Goal for “Raising the Bar” for RCT. Enhance ...
the Buzzer
the Buzzer" for Classroom Dawdling: A One-Year Trial
by pasty-toler
THERAPY 1~, 403--409 (1984) K. State University ...
Collaborative group for Adrenocortical Carcinoma Therapy - COACT - C
Collaborative group for Adrenocortical Carcinoma Therapy - COACT - C
by karlyn-bohler
irst I nternational R andomized trial in locally a...
Risk Factor Modification Post Stroke
Risk Factor Modification Post Stroke
by olivia-moreira
Ron Pellegrino, MD. November 20, 2015. Objectives...
Chee Lee,
Chee Lee,
by olivia-moreira
MBBS (Hons), . MMedSci. (. Clin. . Epid. ), . M...
Trial or Therapy; Rights or Interests?
Trial or Therapy; Rights or Interests?
by myesha-ticknor
Geoff Sharp. … a view from the coalface. 2nd As...
Acquired Resistance Patient Forum
Acquired Resistance Patient Forum
by briana-ranney
September 6, 2014 | Boston. In ALK, ROS1 & EG...
Italian cohort of
Italian cohort of
by test
nivolumab. Expanded Access . Programme. (EAP): ...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by ellena-manuel
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Testicular and
Testicular and
by pamella-moone
E. xtragonadal. Germ . C. ell . T. umors: Focus ...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by giovanna-bartolotta
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
An update on clinical trials and
An update on clinical trials and
by celsa-spraggs
personalised. medicine for pancreas cancer in A...
New Perspectives in Treatment Strategies for Follicular Lymphoma
New Perspectives in Treatment Strategies for Follicular Lymphoma
by olivia-moreira
Introduction. Standard Frontline Therapy for FL. ...
Recent advances in the classification and management of pulmonary small vessel
Recent advances in the classification and management of pulmonary small vessel
by liane-varnes
vasculitides. . Dr. . Aditya. . Jindal. ...
Clinical 101: Clinical trial endpoints:
Clinical 101: Clinical trial endpoints:
by sherrill-nordquist
Selection. , analysis and interpretation. Elizabe...
A Fib begets A fib An Ov
A Fib begets A fib An Ov
by natalia-silvester
erview of AF and Treatment Strategies. Jad. . Sk...
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
by min-jolicoeur
HR Advanced Breast Cancer. Introduction. Restagi...
GreenLight XPS™ Laser Therapy System
GreenLight XPS™ Laser Therapy System
by min-jolicoeur
The GOLIATH Study. The GOLIATH . Study. 1-3. Pros...
Indolent Non-Hodgkin L
Indolent Non-Hodgkin L
by danika-pritchard
ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...
NCI-Molecular Analysis for Therapy Choice
NCI-Molecular Analysis for Therapy Choice
by conchita-marotz
(NCI-MATCH / EAY131). A phase II precision medic...
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
by celsa-spraggs
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
The fundamentals when managning type 2 diabetes
The fundamentals when managning type 2 diabetes
by natalia-silvester
J. Vassallo . (Malta). 15. th. MGSD Congress. 27...
Professor Rury Holman
Professor Rury Holman
by marina-yarberry
University of Oxford, UK. Professor Chang Yu Pan...
Updates in the Treatment of Breast cancer
Updates in the Treatment of Breast cancer
by alexa-scheidler
Mohammad . Jahanzeb. , MD, FACP. Professor of Cli...
CAD/PAD in Primary Care CV Risk in Stable Outpatients
CAD/PAD in Primary Care CV Risk in Stable Outpatients
by stefany-barnette
Stratified by Baseline CV Risk Category. Aspirin ...
Management of asymptomatic carotid stenosis
Management of asymptomatic carotid stenosis
by trish-goza
Thomas C. Hammond M.D., FAAN. UCNS certified in N...
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
by faustina-dinatale
The Changing Landscape of Diabetes Therapy for Ca...
The Role of Antiangiogenic Agents
The Role of Antiangiogenic Agents
by luanne-stotts
The Role of Antiangiogenic Agents in the Changin...
De-escalation versus escalation of antiplatelet therapy in elderly ACS patients: insight from the ANTARCTIC trial.
De-escalation versus escalation of antiplatelet therapy in elderly ACS patients: insight from the ANTARCTIC trial.
by debby-jeon
De-escalation versus escalation of antiplatelet t...
Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have?
Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have?
by marina-yarberry
Expanding Treatment Options in SCCHN: What Role D...
Antibodies, BiTEs , and CARs: the new ABC’s of Myeloma Therapy
Antibodies, BiTEs , and CARs: the new ABC’s of Myeloma Therapy
by aaron
June 6, 2019. Adam D. Cohen, MD. Director, Myelom...
HPI CC: Chest Pain HPI
HPI CC: Chest Pain HPI
by coursion
A 55 year old male with a PMHx of Hyperlipidemia p...
A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy
A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy
by bikersjoker
patients with . advanced breast . cancer and a ger...
GENE THERAPIES IN RARE DISEASEFROM R&D TO REGULATORY APPROVAL ...
GENE THERAPIES IN RARE DISEASEFROM R&D TO REGULATORY APPROVAL ...
by disclaimercanon
ARTICLEAdvancements in science and technology have...